Strong Q3 2026 Results Offset Deal Overhang, but WAIT Stance Remains Prudent

What happened

The DeepValue master report rates McCormick (MKC) a WAIT, citing the Unilever Foods Reverse Morris Trust's $15.7B financing need, antitrust divestiture risk, and modest organic growth, with attractive entry at $45 and trim above $55. A new Seeking Alpha article argues for a Buy, highlighting robust Q3 2026 results—double-digit net sales growth and a double earnings beat—alongside a BBB credit rating and a likely November dividend increase. The article revises fair value to $54, implying 24% upside from current levels, but it does not fully address the master report's concerns about bridge financing, potential regulatory remedies, and volume/mix pressure. Q3 results mark an improvement over Q1 FY26, when volume/mix declined 0.7% and adjusted EPS guidance was only $3.05–$3.13, suggesting the base business may be stabilizing. However, the stock's near-term path remains dominated by deal execution risks, and the bullish case hinges on a clean regulatory process and successful synergy realization, which are not yet assured.

Implication

The Q3 2026 beat indicates that McCormick's underlying operations are improving, potentially supporting the lower end of the master report's valuation range ($52 base case) even if the Unilever deal stalls. However, the current price near $48.40 already reflects some optimism, and the article's $54 fair value assumes a successful deal close without major divestitures, which is far from certain given the $15.7B bridge and HSR review. Investors should monitor for S-4 filing, shareholder vote timing, and any regulatory remedy language, as these will be the primary catalysts for re-rating. Until the financing path becomes clearer and volume trends stabilize, a WAIT rating with a trim level above $55 remains appropriate, as the risk/reward is not sufficiently skewed to justify aggressive buying. The likely November dividend increase adds modest income support, but it does not offset the binary outcome of the merger process.

Thesis delta

The new Q3 2026 results provide evidence that the base business is performing better than the Q1 volume decline suggested, which could raise the floor for the stock and marginally increase the probability of the bull scenario. However, the master report's WAIT thesis remains intact because the key overhangs—Unilever transaction financing, antitrust risk, and potential integration fatigue—are not resolved by a single strong quarter. The article's $54 fair value implicitly assumes a successful deal with full synergies, a premise that still carries substantial uncertainty.